Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
421-440 of 991 trials

Epidermolysis Bullosa Simplex: Diacerein 1% Ointment

We are studying a new ointment for people with generalized Epidermolysis Bullosa Simplex to see if it helps improve skin condition and reduce symptoms. The trial includes both adults and children aged 6 months and older.

Epidermolysis Bullosa Simplex1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteDermatology

Diabetic Kidney Disease: Hyperpolarized MRI Study

We are investigating a new MRI technique to see if it can help classify the progression of diabetic kidney disease. This study aims to improve understanding of kidney function and metabolism in affected individuals.

Diabetic Kidney Disease>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyNephrology

Non-Small Cell Lung Cancer: Neoadjuvant and Adjuvant Treatment Study

We are studying a new treatment approach for patients with resectable non-small cell lung cancer to see if it improves tumor response and safety before and after surgery.

Non-small Cell Lung Cancer (NSCLC)>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Staccato Alprazolam for Prolonged Seizures in Ages 12 and Up

We are studying the safety of Staccato Alprazolam for treating long seizures in children and adults. This trial will help us learn how well it works and its effects on lung health over time.

Prolonged Seizure>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Heart Failure: Finerenone and SGLT2 Inhibitor Study

We are investigating whether a combination of finerenone and an SGLT2 inhibitor can improve health outcomes for hospitalized heart failure patients. This study aims to see if this approach leads to better symptom relief and fewer hospital visits.

Heart Failure1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Heart Failure: Finerenone Study

We are testing the medication finerenone for patients with heart failure who cannot tolerate standard treatments. The study aims to see if it is safe and effective for these individuals.

Heart Failure>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Advanced Lung Cancer: Adagrasib and Pembrolizumab Study

We are testing a new treatment combining adagrasib with pembrolizumab for patients with advanced non-small cell lung cancer with a KRAS G12C mutation. The goal is to see if this combination works better than pembrolizumab alone.

Advanced Non-Small Cell Lung CancerEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Medical Cannabis Aerosol for Diabetic Peripheral Neuropathic Pain

We are studying whether a medical cannabis aerosol can help reduce pain for people with diabetic peripheral neuropathic pain. Participants will compare different doses of THC to a placebo to assess pain relief and quality of life.

Diabetic Peripheral Neuropathic Pain3-6 monthsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteEndocrinologyNeurology

Hidradenitis Suppurativa: Secukinumab Treatment Study

We are investigating the long-term effects of secukinumab on people with moderate to severe hidradenitis suppurativa. This study will help us understand its safety and effectiveness compared to a placebo.

Hidradenitis Suppurativa>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

HER2-Positive Breast Cancer: Zanidatamab vs. Trastuzumab

We are studying whether zanidatamab combined with chemotherapy is more effective and safer than trastuzumab with chemotherapy for patients with metastatic HER2-positive breast cancer who have not responded to previous treatments.

Metastatic HER2-positive Breast Cancer3-6 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Vedolizumab for Children with Moderate to Severe Crohn's Disease

We are studying how well different doses of vedolizumab help children and teenagers with Crohn's disease maintain their health. The goal is to see if it can keep symptoms under control and improve their overall well-being.

Crohn's Disease1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

Ulcerative Colitis and Crohn's Disease: Vedolizumab IV in Kids

We are studying the long-term safety of vedolizumab IV in children and teenagers with ulcerative colitis or Crohn's disease. This research aims to understand its effects on health and quality of life.

Active Ulcerative Colitis or Crohn's Disease>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterology

Idiopathic Pulmonary Fibrosis: Buloxibutid Study

We are testing a new medication, buloxibutid, to see if it helps improve lung function and quality of life for people with idiopathic pulmonary fibrosis. The study compares its effects to a placebo over time.

Idiopathic Pulmonary Fibrosis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Sotagliflozin for Post-Bariatric Hypoglycaemia

We are studying whether sotagliflozin can help people who have low blood sugar after weight loss surgery. Participants will receive either the medication or a placebo to compare effects on blood sugar levels.

Postbariatric Hypoglycemia≤3 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementEndocrinologyInternal Medicine

Pulmonary Arterial Hypertension: Sotatercept Study

We are evaluating the long-term safety of sotatercept for adults with pulmonary arterial hypertension already on treatment. This study will help us understand how well it works when added to existing therapies.

Pulmonary Arterial Hypertension>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiology

Systemic Lupus Erythematosus: Belimumab Study

We are studying the effects of belimumab in adults with early systemic lupus erythematosus to see if it helps improve their condition and reduce steroid use.

Systemic Lupus Erythematosus>2 yearsMonitoring phase (IV)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteRheumatology

Kidney Function: Non-Radioactive Measurement Methods

We are evaluating a new non-radioactive method for measuring kidney function in comparison to traditional radioactive techniques. This study aims to ensure accurate assessments while minimizing radiation exposure.

Chronic Kidney Disease3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementInternal MedicineNephrology

Sickle Cell Disease: Etavopivat Treatment Study

We are evaluating how well etavopivat works for adolescents and adults with sickle cell disease. The study aims to see if it improves symptoms and quality of life compared to a placebo.

Sickle Cell Disease>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Heart Attack Treatment: RTP-026 Study

We are exploring a new medication, RTP-026, for patients who have had a heart attack. The study will assess its safety and effectiveness compared to a placebo.

Heart Attack (Acute Myocardial Infarction)1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Thyroid Eye Disease: Efgartigimod PH20 SC

We are studying a new treatment for adults with thyroid eye disease to see if it reduces eye bulging compared to a placebo. This trial will help us understand its effectiveness and safety.

Thyroid Eye Disease>2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyOphthalmology